|
|||||
|
|
The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies |
|
| Authors: | María Molina-Vega Araceli Muñoz-Garach Francisco J. Tinahones |
| Affiliation: | 1. Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain;2. Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain;3. Centro de Investigacion Biomedica en Red. Fisiopatologia de la Obesidad y Nutricion (CIBERObn CB06/003), Instituto de Salud Carlos III, Madrid, Spain |
| Abstract: | Introduction: Type 2 diabetes (T2D), a multifactorial and chronic disease, requires in an elevated percentage of patients the association of several antidiabetic drugs to achieve optimal glycemic control. Dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium–glucose cotransporter inhibitors (SGLT2i) are new classes of oral antidiabetic drugs developed over the last years. Areas covered: This paper summarizes the safety of DPP-4i and SGLT2i combination therapies. Relevant studies were identified through searches in PubMed. Expert opinion: DPP4i and SGLT2i are antidiabetic drugs that lower blood glucose without causing hypoglycaemia or weight increase. More importantly, cardiovascular trials have clearly demonstrated the cardiovascular safety of DPP4i and a reduction in cardiovascular events with SGLT2i (empagliflozin and canagliflozin). Therefore, the association of both therapeutic groups could be an attractive option to achieve optimal blood glucose control in T2D because of their complementary mechanism of action. Clinical trials evaluating the combination of SGLT2i and DPP4i show that the co-administration of these drugs in fixed-dose combinations in comparison to separate tablets does not carry additional safety concerns that each individual drug, but increases therapeutic effects. Therefore, this antidiabetic combination is a safe and effective therapy for patients with T2D. |
| Keywords: | SGLT-2 inhibitor DPP-4 inhibitor combination safety |